The Dow's Dividend Giants: Yield Isn't Everything
Dan Caplinger, The Motley Fool - Motley Fool - Sun May 18, 8:05AM CDT
Dividends are important, and one of the best things about the Dow Jones Industrials is that every one of the 30 component stocks that make up the Dow pay a dividend. But when it comes to dividends, it is possible to have too much of a good thing...
The Hidden Link Between Obesity and Marijuana
George Budwell, The Motley Fool - Motley Fool - Sun May 18, 7:03AM CDT
Marijuana's uncanny ability to make us feel hungry has long intrigued the medical community. Currently, many states allow marijuana to be prescribed for its therapeutic benefits, especially for patients who have trouble drumming up an appetite. The...
Could a Vaccine-Based Cancer Cure Be Around the Corner?
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 12:40PM CDT
Whether or not you're an avid follower of the health-care sector, there's always something intriguing and innovative going on. Over the past couple of years we've witnessed one tissue engineering company develop a platform that may one day soon...
ASCO 2014: Making and Breaking Cancer Drugs
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri May 16, 1:30PM CDT
As oncology has become the hottest space within pharmaceuticals and biotech, the annual American Society of Clinical Oncology (ASCO) is pretty much now the Super Bowl for companies in this space. Meetings like ASCO certainly do lead to companies...
Merck & Co. Inc. Pays Out All of Its Profits as Dividends. Is This Generous Policy Doomed to Collaps
Anders Bylund, The Motley Fool - Motley Fool - Fri May 16, 1:00PM CDT
In some ways, Merck is the most generous dividend payer on the Dow Jones Industrial Average . That's obviously great for Merck investors -- unless the pharma giant is going too far, of course. Is Merck simply serving shareholders to the best...
Brazil Parkinson's Disease Drug Forecast and Market Analysis to 2022
M2 - Fri May 16, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xcc66k/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - Brazil Drug Forecast and Market Analysis to 2022" report to their offering. The decline in sales is attributed to a private-public partnership (PPP) between Brazil and Boehringer Ingelheim, which will drive down the price of generic pramipexole as the technology to produce the drug is transferred to Brazil's Oswaldo Cruz Foundation (Fiocruz)/Institute of Drug Technology (Farmanguinhos), which will solely be responsible for the country's production of the drug by 2017. Scope - Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Brazil from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the Brazil Parkinson's Disease market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Current and Future Players 9 Market Outlook 10 Appendix Companies Mentioned - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck For more information visit http://www.researchandmarkets.com/research/xc...harmapoint
US Parkinson's Disease Report 2014 - Drug Forecast and Market Analysis to 2022
M2 - Fri May 16, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7wtll/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - US Drug Forecast and Market Analysis to 2022" report to their offering. Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. Advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period. This market is expected to grow faster than any other market, including the 5EU, due in part to the introduction of two brands already in use in the 5EU, Neupro and Duodopa, launched in the US at the beginning of the forecast in 2012 and 2014, respectively. Other factors responsible for growth in this market are an aging population that contributes to an increased prevalence of Parkinson's disease in the US and the launch of six new pipeline agents (in addition to Duodopa and Neupro). Scope - Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in US including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in US from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the US Parkinson's Disease market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment - Levodopa Combination Therapy - Product Profiles - COMT Inhibitors - Dopamine Agonists - Requip/Requip XL (ropinirole) - Product Profiles - MAO-B Inhibitors - Product Profiles - Adenosine 2A Inhibitor 6 Opportunity and Unmet Need 7 Pipeline Assessment - Safinamide - Tozadenant - CVT-301 - Rytary/IPX066 - Opicapone - Mavoglurant/AFQ056 - CD/LD-GR - Other Late-Stage Pipeline Products 8 Current and Future Players - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck 9 Market Outlook 10 Appendix For more information visit http://www.researchandmarkets.com/research/w7...harmapoint
Chimerix Regains Worldwide Rights to CMX157
GlobeNewswire - Fri May 16, 7:00AM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it has regained the worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate, from Merck, known as MSD outside the United States and Canada. Following a routine pipeline portfolio assessment, Merck made the decision to no longer pursue development of CMX157.
Global Ovarian Cancer Therapeutics in Major Developed Markets to 2020: Population Growth and Inflation to Drive Market
M2 - Fri May 16, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hln2d6/ovarian_cancer) has announced the addition of the "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies" report to their offering. Population Growth and Inflation to Drive Market Global Ovarian Cancer Therapeutics in Major Developed Markets to 2020 has identified and analyzed 10 promising late-stage pipeline drugs . However, of these 10, only Telik's Telcyta has been shown to improve median patient Overall Survival (OS); however, questions raised over the validity of the data mean that the drug is not expected to be approved within the forecast period of 2013-2020. Further Phase III trials of the drug are required, for which Telcyta is currently seeking corporate partners. Most of the late-stage drugs provide no clinical benefit to patients, with the best responses being mild to moderate improvements in Progression-Free Survival (PFS) in comparison with standard-of care treatment. In the projected scenario, those drugs that have been shown to provide an improvement in PFS will be approved in the EU, Canada and Japan. These are Vynfinit, olaparib and Trebananib. This is in line with the most recent drug approvals in these markets: Avastin and Yondelis, which were approved on the basis of improved PFS. However, the expected high cost of these drugs and their minimal clinical benefit, are expected to create a negative opinion of them among healthcare professionals and regulatory bodies in these three geographies, limiting their prescription volumes. In the US, the improvements in PFS observed with Yondelis and Avastin were not sufficient for either drug to be granted approval in the US. However, despite its refusal, Avastin is approved for other indications within oncology, with evidence that the drug is prescribed off-label for the treatment of Ovarian Cancer (OC) in the US, contributing significantly to the current market (Burger, 2007). The inflation of Avastin, which costs up to $100,000 for a course of treatment, is expected to be a major contributor to market growth in the US and globally. Given the similar lack of OS benefit with current late-stage pipeline drugs, it is unlikely the aforementioned late-stage pipeline drugs will be approved in the US within the forecast period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products - Carboplatin - Paclitaxel - Gemcitabine - Topotecan - Pegylated Liposomal Doxorubicin - Yondelis - Avastin 4 Product Pipeline 5 Late-Stage Drugs in Developmental Pipeline - Niraparib - Olaparib - Abagovomab - Vargatef - Trebananib - Farletuzumab - Vynfinit - Telcyta - Karenitecin 6 Market Forecast 7 Drivers and Barriers - High Number of Candidates in Drug Development - High Unmet Clinical Need - Incentives for Orphan Drug Development - Potential Changes to Clinical Trial Design - Decreasing Incidence Rates - Lack of Cell Lines - High Heterogeneity of the Disease - High Cost of Novel Drugs 8 Deals - Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338 - PharmaMar Enters into Licensing Agreement with Janssen for Yondelis - Hana Enters into Licensing Agreement with Tekmira - AstraZeneca Enters into Licensing Agreement with Merck for MK-1775 - Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug - Oasmia Enters into Licensing Agreement with Medison for Paclical - Orion Enters into Agreement with Oasmia - Ohio University Enters into Licensing Agreement with Phosplatin - Genta Enters into Licensing Agreement with Daiichi Sankyo - Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research - NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300 - Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug - Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre - Almac Discovery Enters into an Agreement with Queen's University Belfast for Drug Discovery 9 Appendix For more information visit http://www.researchandmarkets.com/research/hl...ian_cancer
Pipeline Breakdown: Merck & Co. Inc.
Brian Orelli, The Motley Fool - Motley Fool - Thu May 15, 5:30PM CDT
Merck recently held its analyst day, updating analysts and investors listening in on its pipeline. While there weren't any major announcements -- no high-profile clinical trial results were announced -- there were a few tidbits that investors...
Could Bristol-Myers End Up Acquiring Celldex?
Todd Campbell, The Motley Fool - Motley Fool - Thu May 15, 1:30PM CDT
Celldex 's shares jumped by more than a quarter following news that Bristol-Myers has paid Celldex $5 million up front and will pay half of development costs for a new study that teams Bristol's PD-1 drug nivolumab up with Celldex's promising...
Parkinson's Disease - 5EU Drug Forecast and Market Analysis to 2022: Introduction of A2A antagonists in 2019, will bring in an extra $24.7m in sales in 2022
M2 - Thu May 15, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8h86cj/pharmapoint) has announced the addition of the "PharmaPoint: Parkinson's Disease - 5EU Drug Forecast and Market Analysis to 2022" report to their offering. Although France has a lower-than-average rate of generic substitution compared with other parts of Europe, increasing pressures from its aging population and increased disease burden are forcing governments to institute cost-saving measures. The market leader therapies in Germany are all no longer patent protected and include the class of oral dopamine agonists. While the overall pharmaceutical market in Italy is shrinking, the medical device market in Italy is growing. This market growth will be driven by six new product launches, and by an aging population, resulting in an increased prevalence of Parkinson's disease in Spain. Population growth and the aging population will continue to build steady growth in the UK Parkinson's disease market and six additional product launches, including the introduction of A2A antagonists in 2019, will bring in an extra $24.7m in sales in 2022. Scope - Overview of Parkinson's Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in 5EU from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Parkinson's Disease market. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Symptoms 4 Disease Management - Treatment Synopsis - Parkinson's Disease Assessment Scales - Diagnosis and Treatment of Parkinson's Disease by Country 5 Competitive Assessment - Product Profiles - Levodopa Combination Therapy - Product Profiles - COMT Inhibitors - Dopamine Agonists - Product Profiles - MAO-B Inhibitors - Product Profiles - Adenosine 2A Inhibitor - Product Profiles - Other Therapies 6 Opportunity and Unmet Need - Treatment of Motor Complications - Dyskinesias and OFF Episodes - Treatment of Non-Motor Symptoms and Dementia - Neuroprotective/Disease-Modifying Agents - Improved Drug Formulations - Identification of Reliable Biomarkers - Improved Clinical Trial Design 7 Pipeline Assessment - Safinamide - Tozadenant - CVT-301 - Rytary/IPX066 - Opicapone - Mavoglurant/AFQ056 - CD/LD-GR - Other Late-Stage Pipeline Products 8 Current and Future Players - Merck - Roche - AbbVie - UCB - GlaxoSmithKline - Novartis - Orion - Newron - Civitas - Impax - Lundbeck 9 Market Outlook - Driver: Aging Population - Driver: Launch of Products that Will Add Patient Share - Driver: High Compliance Rates - Driver: History of Success in PD Market - Driver: Innovation and Technological Advances - Driver: High Degree of Polypharmacy - Barrier: Lack of Understanding of Pathophysiology - Barrier: Lack of Efficacy of New Compounds - Barrier: Strategic Decisions to Leave CNS Space for Several Large Pharma Companies 10 Appendix For more information visit http://www.researchandmarkets.com/research/8h...harmapoint
Research and Markets: Global PCOS Drugs Market 2014-2018 with Bristol Myers Squibb, Merck & Co., Novartis AG, Sanofi SA & Teva Pharmaceutical Dominating
Business Wire - Thu May 15, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/th4mp7/global_pcos_drugs) has announced the addition of the "Global PCOS Drugs Market 2014-2018" report to their offering.
Global PCOS Drugs Market 2014-2018 with Bristol Myers Squibb, Merck & Co., Novartis AG, Sanofi SA & Teva Pharmaceutical Dominating
M2 - Thu May 15, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x7lhbh/global_pcos_drugs) has announced the addition of the "Global PCOS Drugs Market 2014-2018" report to their offering. PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS. There has been a gradual increase in awareness of PCOS among the female population over the years. The acceptability of PCOS drugs is expected to rise because of the increasing public awareness of the syndrome and the need to treat it. This is expected to result in increasing drug penetration. In the recent past, there have been several awareness and educational programs specifically targeting patients with PCOS. For instance, September is celebrated annually as PCOS Awareness Month by the PCOS Foundation. The aim of the PCOS Foundation is to spread awareness through public and professional education programs to improve diagnosis and eliminate the lifetime risks associated with PCOS. The PCOS Foundation hosts a PCOS Awareness 5K Fun Run every September, which acts as part of the awareness campaign and encourages media discussion about PCOS. Thus, the increasing awareness and resultant higher treatment-seeking rates for PCOS are expected to contribute to the growth of the market. According to the report, the Global PCOS Drugs market is driven by several factors, of which an increase in the number of patients is one of the major drivers. Co-morbid conditions such as diabetes, obesity, and other cardiovascular complications lead to an increase in the number of PCOS patients. Further, the report states that lack of approved drugs for the treatment of PCOS is one of the main challenges. Since there are no specific approved products for the treatment of PCOS, the market is mainly dependent on treating conditions associated with PCOS by using various generic and off-label products. Key Vendors - Bristol Myers Squibb Co. - Merck & Co. Inc. - Novartis AG - Sanofi SA - Teva Pharmaceutical Inc. Other Prominent Vendors - AstraZeneca plc - Catalysis SL - Crinetics Pharmaceuticals Inc. - Dexa Medica Group - EffRx Inc. - Neurocrine Biosciences Inc. For more information visit http://www.researchandmarkets.com/research/x7...pcos_drugs
Boston Scientific to spend $415M on Bayer division
AP - Thu May 15, 7:22AM CDT
NATICK, Mass. (AP) — Boston Scientific will spend $415 million to buy the Bayer division that makes treatments for diseased blood vessels outside the heart.
Life Science Reagents Market Forecasts 2013-2019: PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents
M2 - Thu May 15, 6:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3wdhc3/life_science) has announced the addition of the "Life Science Reagents Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report covers the market analysis for various reagents used in the life science industry. Continuous innovation in biotechnology is driving the life science reagents market towards remarkable growth. The stakeholders for this study include manufacturers and providers of life science reagents. The global life science reagents market is categorized on the basis of various products that are commercially available and end users of life science reagents. The different product categories covered in this report include polymerase chain reaction (PCR) reagent kits, cell and tissue culture reagents, flow cytometry reagents, chromatography reagents, in-vitro diagnostic (IVD) reagents and others (gene expression reagents, mass spectroscopy reagents and transfection reagents). The end users for this market comprise commercial and contract manufacturers, research and academic institutes, hospital and clinical laboratories, and forensic laboratories. A detailed market analysis and revenue forecast for these segments has been provided in this study, in terms of USD million for the period 2011 to 2019. The report also provides the compounded annual growth rate (CAGR %) for each product type and end user segment for the forecast period 2013 to 2019, while the market size estimations have been made considering 2012 as the base year. The report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Abbott Laboratories, Agilent Technologies, Lonza Group Ltd., Promega Corporation, Sigma Aldrich Corporation, Merck Millipore, Siemens Healthcare and Bio-Rad Laboratories, Inc. The global life science reagents market is segmented as follows: Life Science Reagents Market, by Product Type - Polymerase chain reaction (PCR) reagent kits - Cell and tissue culture reagents - Flow cytometry reagents - Electrophoresis reagents - Chromatography reagents - In-vitro diagnostics (IVD) reagents - Others (gene expression reagents, mass spectroscopy reagents and transfection reagents) Life Science Reagents Market, by End User - Commercial and contract manufacturers - Research and academic institutions - Clinical laboratories - Forensic laboratories Companies Mentioned - Abbott Laboratories, Inc. - Agilent Technologies, Inc. - Becton, Dickinson and Companys - Beckman Coulter, Inc. - bioMerieux, Inc. - Bio-Rad Laboratories, Inc. - F. Hoffman-La Roche, Ltd. - GE Healthcare Ltd. - Life Technologies Corporation - Lonza Group Ltd. - Merck Millipore - Meridian Life Science, Inc. - PerkinElmer, Inc. - Promega Corporation - Siemens Healthcare - Sigma-Aldrich Corporation - Sysmex Corporation - Waters Corporation For more information visit http://www.researchandmarkets.com/research/3w...fe_science
ALK's partner for North America, Merck, announces launch of RAGWITEK(tm) in Canada
GlobeNewswire - Thu May 15, 6:02AM CDT
ALK (ALKB
SFW Capital Partners Makes a Strategic Investment in Essen BioScience
Business Wire - Thu May 15, 5:00AM CDT
SFW Capital Partners, a specialized private equity firm that invests with management in mid-sized companies providing analytical tools and related services, today announced an investment in Essen BioScience, Inc. SFW is partnering in this investment with Essen's co-founders, Kirk Schroeder and Brad Neagle, who serve as the current President and Vice-President of Operations and Engineering respectively, and its management team. As a team, the partners at SFW have supported some of the most successful and well-regarded companies in the analytical instrumentation market, including Mettler-Toledo International, Waters Corporation, Spectro Scientific and Industrial Dynamics Company ("filtec"
Global Flow Cytometry Market Forecasts & Opportunities, 2020: Latest Trends for the $6.5 Billion Industry
M2 - Thu May 15, 2:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gww4mg/flow_cytometry) has announced the addition of the "Flow Cytometry Market (Products, Application, Technology, and Users) - Current Trends, Opportunities, Industry Analysis, Size, Share and Global Forecast, 2012-2020" report to their offering. Flow Cytometry Market will Reach $6.5 Billion Globally by 2020 with Increasing Precision. As per the study, the flow cytometry market valued $3 billion in 2012 is further expected to reach $6.5 billion by 2020 growing at a CAGR of 30.9%. Increasing needs to enhance precisions and produce faster results as well as need for compact devices are compelling the clinical and diagnostic organization to adopt innovative technologies. Though popularity has been gained in the application field of life science industry, the cost of the instrument is impeding the growth. Due to this, many researchers are still reluctant in adopting this technology in their research work. Moreover, advancing technologies that has brought complex instrumentation requires highly skilled personals to operate these instruments. Immunotyping and signal transduction, for example, have been playing a significant role in medical diagnostics. However, conventional technologies used, have limited the accuracy and impacted the result deliverance time of the diagnosis performed. Improving therapeutic scenario is equally attracting focus on early diagnostic tools. Currently, many cancer types have various treatment options; however, this depends on the time of diagnosis and the stage of the cancer. Flow cytometry has been one of the most prevalent technologies which offer solutions for most of the problems discussed above. Key factors restraining the market include high instrument costs and size, lack of awareness among probable users and need for trained personnel. North America accounted for the largest share of revenue i.e. 43.5% of the overall Global flow cytometry market at $1.2 billion in 2011. The region is further expected to attain a market size of $2.8 billion by 2020 growing at a CAGR of 10.1%. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Flow Cytometry Market Overview Chapter 4 Flow Cytometry Market By Product Chapter 5 Flow Cytometry Market By Technology Chapter 6 Flow Cytometry Market By Application Chapter 7 Flow Cytometry Market By End User Chapter 8 Flow Cytometry Market By Geography Chapter 9 Company Profiles - Advanced Analytical Technologies Inc (AATI) - Amnis Corporation - Beckman Coulter - Becton - Dickinson & Co. - Ebioscience Inc. - Life Technologies Corporation - Luminex Corporation - Merck Millipore - Morphosys AG - Partec GmbH For more information visit http://www.researchandmarkets.com/research/gw..._cytometry
Bristol, Merck, AstraZeneca Bring New 'Checkpoint Inhibitor" Data to ASCO '14
at The Street - Wed May 14, 4:00PM CDT
New classes of drugs designed to dismantle cloaking mechanisms used by cancer cells to hide from a patient's immune system will dominate the buzz at this year's ASCO annual meeting.